CriticalFirst-generation antihistamine with anxiolytic activity×Third-generation fluoroquinolone
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Levofloxacin, like other fluoroquinolones, is also associated with QT prolongation and infrequent cases of arrhythmia. Post-marketing cases of ventricular arrhythmia and torsade de pointes occurred mostly in people with risk factors for QT prolongation (levofloxacin SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish hydroxyzine SmPC names levofloxacin among the antibiotics that raise the risk of arrhythmia when given with hydroxyzine (AEMPS). The documents of both drugs describe no metabolic interaction between them.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular arrhythmia and torsade de pointes cause palpitations, dizziness and fainting, and ventricular tachycardia can end in cardiac arrest (levofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Older people and women may be more sensitive to QT-prolonging drugs (levofloxacin SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval and names levofloxacin (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The levofloxacin documents do not contraindicate the pair: the Spanish levofloxacin SmPC advises caution with other QT-prolonging drugs (levofloxacin SmPC, AEMPS). The US hydroxyzine label also only advises caution with QT-prolonging drugs, including certain antibiotics (hydroxyzine label, US Food and Drug Administration, FDA); the Spanish hydroxyzine SmPC is stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Use levofloxacin with caution in congenital long QT syndrome, uncorrected low potassium or magnesium and heart disease, and in older people and women (levofloxacin SmPC, AEMPS). Use hydroxyzine at the lowest effective dose for the shortest time, and stop it if signs of arrhythmia appear (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Levofloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 5c6c117c-9d91-48f4-9aaa-ee70b99218c2, version 3, 06/2026, section 5.11 (Prolongation of the QT Interval)
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage
- AEMPS: Ficha técnica: Levofloxacino, Tavanic 500 mg (nº registro 62065), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62065 (Tavanic 500 mg comprimidos recubiertos con película, Sanofi Aventis), revisión 08/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9